Pfizer Inc.

NYSE:PFE  
39.58
+0.38 (+0.98%)
4:03:58 PM EDT: $39.50 -0.08 (-0.19%)
Products, Other Pre-Announcement

Pfizer says Expects To Hear Back Shortly From The FDA On Its Expanded EUA Application To Include Adolescents For Covid-19 Vaccine

Published: 05/04/2021 11:55 GMT
Pfizer Inc. (PFE) - Pfizer Says Expect to Hear Back Shortly From FDA on Application for Expanded Eua for Its Covid-19 Vaccine to Include Individuals 12 to 15 Years of Age.
Pfizer Plans to Begin Clinical Testing of Two Potential Mrna Flu Vaccine Approaches Expected in Q3 2021.
Pfizer Says to Have Definitive Readouts and Submit for Eua for Two Cohorts, Including Children 2-5 Years of Age and 5-11 Years of Age, in September.
Pfizer CEO Says in Prepared Remarks That Lasting Demand Similar to That of Flu Vaccines is Likely for Covid-19 Vaccine.
Pfizer Says to Expect Phase 2 Safety Data From Its Ongoing Study in Pregnant Women by Late July/early August.
Pfizer Says Submitted New Data and Could Receive Update to Eua Allowing Covid-19 Vaccine to Be Stored at Standard Refrigerator Temperatures for Up to 4 Weeks.
Pfizer Says Working on New Formulation of Their Covid-19 Vaccine That Could Potentially Be Stored at Standard Refrigerator Temperatures for Up to 10 Weeks.